Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2025 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter...
February 04, 2025 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the company approved the grant of equity awards to three new employees with a...
January 27, 2025 16:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan)...
January 13, 2025 09:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net...
January 10, 2025 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces Keli Walbert to Join the Board of Directors

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms....
January 07, 2025 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
January 06, 2025 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on...
December 06, 2024 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
November 27, 2024 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences: ...
November 12, 2024 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare...